Format

Send to

Choose Destination
Curr Opin Immunol. 2014 Apr;27:1-7. doi: 10.1016/j.coi.2013.12.005. Epub 2014 Jan 14.

Regulatory T cells in cancer immunotherapy.

Author information

1
Experimental Immunology, WPI Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan.
2
Experimental Immunology, WPI Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan. Electronic address: shimon@ifrec.osaka-u.ac.jp.

Abstract

FOXP3(+)CD25(+)CD4(+) regulatory T (Treg) cells, crucial for the maintenance of immunological self-tolerance, are abundant in tumors. Most of them are chemo-attracted to tumor tissues, expanding locally and differentiating into a Treg-cell subpopulation that strongly suppresses the activation and expansion of tumor-antigen-specific effector T cells. Several cancer immunotherapies targeting FOXP3(+)CD4(+) Treg cells, including depletion of Treg cells, are currently being tested in the clinic. In addition, clinical benefit of immune-checkpoint blockade, such as anti-CTLA-4 monoclonal antibody therapy, could be attributed at least in part to depletion of FOXP3(+)CD4(+) Treg cells from tumor tissues. Thus, optimal strategies need to be established for reducing Treg cells or attenuating their suppressive activity in tumor tissues, together with activating and expanding tumor-specific effector T cells.

PMID:
24413387
DOI:
10.1016/j.coi.2013.12.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center